We report the design and synthesis of triazole-polyphenol hybrid compounds 1 and 2 as inhibitors of the FabG4 (Rv0242c) enzyme of Mycobacterium tuberculosis for the first time. A major advance in this field occurred only a couple of years ago with the X-ray crystal structure of FabG4, which has helped us to design these inhibitors by the computational fragment-based drug design (FBDD) approach. Compound 1 has shown competitive inhibition with an inhibition constant (Ki) value of 3.97 ± 0.02 μM. On the other hand, compound 2 has been found to be a mixed type inhibitor with a Ki value of 0.88 ± 0.01 μM. Thermodynamic analysis using isothermal titration calorimetry (ITC) reveals that both inhibitors bind at the NADH co-factor binding domain. Their MIC values, as determined by resazurin assay against M. smegmatis, indicated their good anti-mycobacterial properties. A preliminary structureâactivity relationship (SAR) study supports the design of these inhibitors. These compounds may be possible candidates as lead compounds for alternate anti-tubercular drugs. All of the reductase enzymes of the Mycobacterium family have a similar ketoacyl reductase (KAR) domain. Hence, this work may be extrapolated to find structure-based inhibitors of other reductase enzymes.
我们首次报道了三唑-多
酚混合化合物1和2的设计与合成,作为结核分枝杆菌FabG4(Rv0242c)酶的
抑制剂。该领域的一项重大进展发生在几年前,FabG4的X射线晶体结构的公布帮助我们通过计算片段药物设计(F
BDD)方法设计了这些
抑制剂。化合物1表现出竞争抑制,其抑制常数(Ki)值为3.97 ± 0.02 μM。另一方面,化合物2被发现为混合型
抑制剂,Ki值为0.88 ± 0.01 μM。使用等温滴定热量计(ITC)进行的热力学分析显示,这两种
抑制剂都在
NADH辅因子结合域结合。通过对M. smegmatis进行的
罗丹明B实验确定的最小抑菌浓度(MIC)值表明它们具有良好的抗分枝杆菌特性。初步的结构-活性关系(
SAR)研究支持了这些
抑制剂的设计。这些化合物可能作为替代抗结核药物的先导化合物候选者。结核分枝杆菌家族的所有还原酶都有类似的酮酰还原酶(KAR)结构域。因此,这项工作可以外推以寻找其他还原酶的基于结构的
抑制剂。